Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
Aritinercept was well tolerated at all dose levels tested. There were no treatment-related Grade ≥3 adverse events, there were no treatment‑related serious adverse events (SAEs) and there were no discontinuations due to treatment-related adverse events. Adverse events that occurred in more than one subject included injection site reactions (24% aritinercept, 13% placebo), headache (11% aritinercept, 7% placebo), upper respiratory tract infection (7% aritinercept, 0% placebo) and back pain (4% aritinercept, 0% placebo). All injection site reactions were Grade 1.
Single doses of aritinercept led to robust and long-lasting reductions in immunoglobulins (antibodies). Specifically, mean reductions from baseline to Day 28 of up to 48%, 55% and 20% were observed for immunoglobulin A (IgA), immunoglobulin M (IgM) and immunoglobulin G (IgG), respectively.
'Dual inhibition of BAFF and APRIL to modulate B cells, including plasma cells, holds great promise in the treatment of a wide range of autoimmune immune diseases where these cells produce disease-causing autoantibodies,' said Dr. Greg Keenan, Chief Medical Officer of Aurinia. 'Based on today's positive results, which indicate robust and long‑lasting pharmacodynamic effects supportive of once-monthly dosing, we plan to initiate clinical studies of aritinercept in at least two autoimmune diseases in the second half of this year.'
Webcast & Conference Call Details
A webcast and conference call will be hosted today, June 30, at 8:30 a.m. ET. The link to the webcast is available here. To join the conference call, please dial 877-407-9170/+1 201-493-6756. Click here for participant International Toll-Free access numbers. A replay of the webcast will be available on Aurinia's website.
About Aurinia
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA‑approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.
Forward-Looking Statements
This press release contains forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable U.S. securities law. We caution investors that forward-looking statements are based on management's expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with the development of aritinercept and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances. Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia's most recent Annual Report on Form 10-K and its other public available filings available by accessing the Canadian Securities Administrators' System for Electronic Document Analysis and Retrieval (SEDAR) website at www.sedarplus.ca or the U.S. Securities and Exchange Commission's Electronic Document Gathering and Retrieval System (EDGAR) website at www.sec.gov/edgar, and on Aurinia's website at www.auriniapharma.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 minutes ago
- Business Wire
Lighter Capital Adds ShareVault to Its Exclusive Partner Perks Program
LOS GATOS, Calif.--(BUSINESS WIRE)--ShareVault, the secure document sharing and virtual data room (VDR) platform built for high-stakes transactions, today announced a new partnership with Lighter Capital, a leading growth capital provider for early-stage tech startups. As part of the collaboration, ShareVault joins Lighter Capital's Partner Perks Program, which offers founders access to discounted tools and services valued at over $200,000. Founders shouldn't wait until they're in diligence mode to think about how they manage documents. Share Lighter Capital-backed companies can now take advantage of ShareVault's secure, intuitive platform to manage due diligence, fundraising, investor updates, and strategic partnerships. ShareVault is trusted globally by dealmakers for its speed, simplicity, and enterprise-grade security. 'We're excited to partner with Lighter Capital and support founders navigating fundraising and growth,' said Steven Monterroso, CEO of ShareVault. 'ShareVault helps teams move faster, protect sensitive data, and present a more professional, deal-ready presence to investors and buyers.' Designed for early-stage and scaling companies, the perks program gives founders access to best-in-class tools without sacrificing runway. ShareVault's inclusion empowers Lighter Capital's portfolio companies to proactively manage critical business processes that often get overlooked—until it's too late. 'Founders shouldn't wait until they're in diligence mode to think about how they manage documents,' said Tanner Kovacevich, VP of Sales. 'ShareVault makes it easier to stay organized from day one. They're a valuable addition to our perks program.' About Lighter Capital Lighter Capital is the pioneer of revenue-based financing and a leading growth partner for SaaS companies. Since 2010, the lending company has provided hundreds of millions of dollars to over 600 U.S., Canadian, and Australian tech startups. Through its funding platform, ecosystem, and Partner Perks Program, Lighter Capital helps founders accelerate growth—on their terms—without dilution or loss of control. Learn more at: About ShareVault ShareVault is a secure document sharing platform known as a Virtual Data Room (VDR) built for high-stakes transactions across all industries. Professional dealmakers trust ShareVault for M&A, capital raises, litigation, licensing, and compliance. The platform empowers teams to move faster, stay organized, and close with confidence. More than just a VDR, ShareVault is a deal enablement platform that helps companies streamline due diligence, maximize valuation, and signal to investors, buyers, and partners that they're secure, deal-ready, and easy to work with. With enterprise-grade security, intuitive workflows, and tools like AI-powered redaction, Clickwrap NDAs, and audit-grade tracking, ShareVault is changing the game for how deals get done. Learn more at:
Yahoo
33 minutes ago
- Yahoo
KBRA Assigns Preliminary Ratings to GCAT 2025-INV3 Trust
NEW YORK, August 11, 2025--(BUSINESS WIRE)--KBRA assigns preliminary ratings to 59 classes of mortgage-backed notes from GCAT 2025-INV3 Trust. The GCAT 2025-INV3 mortgage loans are secured by first liens on non-owner occupied (NOO) investor properties and second homes. The loans were underwritten to agency guidelines. The pool comprises 974, first-lien, fixed rate residential mortgage loans as of the cut-off date. The pool is characterized by moderate borrower equity in each mortgaged property, as evidenced by the WA original LTV of 75.0%. The weighted average original credit score is 776, which is within the prime mortgage range. KBRA's rating approach incorporated loan-level analysis of the mortgage pool through its Residential Asset Loss Model (REALM), an examination of the results from third-party loan file due diligence, cash flow modeling analysis of the transaction's payment structure, reviews of key transaction parties and an assessment of the transaction's legal structure and documentation. This analysis is further described in our U.S. RMBS Rating Methodology. To access ratings and relevant documents, click here. Click here to view the report. Recent Publications RMBS KCAT GCAT 2025-INV3 Tear Sheet Methodologies Structured Finance: Global Structured Finance Counterparty Methodology RMBS: U.S. RMBS Rating Methodology ESG Global Rating Methodology Disclosures Further information on key credit considerations, sensitivity analyses that consider what factors can affect these credit ratings and how they could lead to an upgrade or a downgrade, and ESG factors (where they are a key driver behind the change to the credit rating or rating outlook) can be found in the full rating report referenced above. A description of all substantially material sources that were used to prepare the credit rating and information on the methodology(ies) (inclusive of any material models and sensitivity analyses of the relevant key rating assumptions, as applicable) used in determining the credit rating is available in the Information Disclosure Form(s) located here. Information on the meaning of each rating category can be located here. Further disclosures relating to this rating action are available in the Information Disclosure Form(s) referenced above. Additional information regarding KBRA policies, methodologies, rating scales and disclosures are available at About KBRA Kroll Bond Rating Agency, LLC (KBRA), one of the major credit rating agencies (CRA), is a full-service CRA registered with the U.S. Securities and Exchange Commission as an NRSRO. Kroll Bond Rating Agency Europe Limited is registered as a CRA with the European Securities and Markets Authority. Kroll Bond Rating Agency UK Limited is registered as a CRA with the UK Financial Conduct Authority. In addition, KBRA is designated as a Designated Rating Organization (DRO) by the Ontario Securities Commission for issuers of asset-backed securities to file a short form prospectus or shelf prospectus. KBRA is also recognized as a Qualified Rating Agency by Taiwan's Financial Supervisory Commission and is recognized by the National Association of Insurance Commissioners as a Credit Rating Provider (CRP) in the U.S. Doc ID: 1010762 View source version on Contacts Analytical Contacts Edward DeVito, Senior Managing Director (Lead Analyst)+1 Bianca Rexach, Associate Director+1 Sharif Mahdavian, Managing Director (Rating Committee Chair)+1 Business Development Contact Daniel Stallone, Managing Director+1
Business Wire
34 minutes ago
- Business Wire
Momentus Securities and Mesirow Help Issue One of the Largest CDFI Bond Offerings Ever: $122.75 Million With An A+ Rating
NEW YORK--(BUSINESS WIRE)--Momentus Securities, LLC, and Mesirow Financial, Inc., have structured and managed one of the largest bond offerings ever by a community development financial institution, or CDFI. By working with Momentus Securities, community lenders can issue bonds and use the funding for a variety of needs, while bond investors can recoup their loan and receive interest payments. Share Capital Impact Partners, one of the nation's foremost CDFIs, has issued $122,750,000 aggregate principal amount of Taxable Bonds, Series 2025-1 (the 'Bonds'), which closed on July 30, 2025. The Bonds were rated A+ by S&P Global. The Bonds were issued in two tranches, with $54,000,000 aggregate principal amount issued at an annual interest rate of 5.335% and maturing on August 1, 2030; and $68,750,000 aggregate principal amount issued at an annual interest rate of 5.999% and maturing on August 1, 2035. Capital Impact Partners will use net proceeds from the issuance of the Bonds to repay outstanding debt. By tapping into the capital markets to create balance sheet flexibility and further diversifying its debt sources, this transaction allows Capital Impact Partners to expand its lending, investments, and programmatic efforts to better support the creation and expansion of small businesses and community facilities in communities nationwide. 'Community development financial institutions, and other community lenders such as certified development companies (CDCs) and credit unions, need more liquidity in order to help support economic growth throughout the United States, but they have long been unable to utilize the mainstream capital markets as a resource,' said Jaime Aldama, President of Momentus Securities, an SEC-registered broker-dealer, a MSRB-registered municipal advisor, and a FINRA/SIPC member. 'We hope this successful bond closing will demonstrate the value of transactions like these for both the issuer and the investors.' 'The success of Capital Impact Partners' bond issuance is a testament to the organization, its financial strength and its impact," said Brian Prater, Managing Director, Mesirow Public Finance. "Mesirow was honored to partner with Momentus Securities to provide a new channel for Capital Impact Partners to access the capital markets.' Historically, impact-focused organizations have had limited exposure and access to the capital markets. The lending done by these organizations is often not at a scale that appeals to investors, nor has it been cost-effective for these organizations to utilize the capital markets to obtain more liquidity. Learn more about how bond issuances can help community lenders, and the other ways Momentus Securities connects mission-driven lenders with institutional investors, at All investing involves risks, including possible loss of the principal amount invested. With fixed-income securities such as bonds, interest rates and bond prices tend to move in opposite directions. When interest rates fall, bond prices typically rise and conversely when interest rates rise, bond prices typically fall. When interest rates are at low levels, there is risk that a sustained rise in interest rates may cause losses to the price of bonds that you own. At maturity, however, the issuer of the bond is obligated to return the principal to the investor. The longer the maturity of a bond, the greater the degree of a price or market value change resulting from a change in interest rates (also known as duration risk). Bond investors should carefully consider risks such as interest rate risk, credit risk, liquidity risk and inflation risk before investing in a particular bond. About Momentus Securities Momentus Securities, an SEC-registered broker-dealer, a MSRB-registered municipal advisor, and a FINRA/SIPC member, offers a range of financial products and services to support its mission of connecting mainstream capital sources and impactful investment opportunities. These services include debt and equity capital raising, asset-backed and structured finance as well as corporate finance and advisory services. Momentus Securities seeks to bolster the mission-driven investing space by addressing the current scale and liquidity limitations in the sector that inhibit the deployment of institutional capital. Momentus Securities is part of the Momentus Capital branded family of organizations, which also include, among other organizations, Capital Impact Partners (a nonprofit Community Development Financial Institution, or CDFI) and CDC Small Business Finance (a leading SBA Community Advantage Small Business Lending Company, or CA SBLC). About Mesirow Mesirow is an independent, employee-owned financial services firm founded in 1937. Headquartered in Chicago, with offices around the world, we serve clients through a personal, custom approach to reaching financial goals and acting as a force for social good. With capabilities spanning Private Capital & Currency, Capital Markets & Investment Banking, and Advisory Services, we invest in what matters: our clients, our communities and our culture.
